UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) April 3, 2006
--------------------------
GENELABS TECHNOLOGIES, INC.
- -------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
California 0-19222 94-3010150
- -------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
505 Penobscot Drive, Redwood City, California 94063
- -------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (650) 369-9500
----------------------------
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of
the following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 2.02 Results of Operations and Financial Condition.
On April 3, 2006, Genelabs Technologies, Inc. announced its financial
results for the fourth quarter and year ended December 31, 2005. A copy of the
related press release is furnished as Exhibit 99.1 hereto.
The information in this Form 8-K (including Exhibit 99.1) shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934 (the "Exchange Act") or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth
by specific reference in such a filing.
Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
Exhibit Number Description
- -------------- -----------
99.1 Press Release, dated April 3, 2006, entitled "Genelabs
Technologies Reports 2005 Year-End and Fourth Quarter
Financial Results"
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENELABS TECHNOLOGIES, INC.
By: /s/ Matthew M. Loar
-----------------------------
Name: Matthew M. Loar
Title: Chief Financial Officer
Date: April 4, 2006
EXHIBIT INDEX
Exhibit Number Description
- -------------- -----------
99.1 Press Release, dated April 3, 2006, entitled "Genelabs
Technologies Reports 2005 Year-End and Fourth Quarter
Financial Results"
EXHIBIT 99.1